Viking Therapeutics, Inc. (NASDAQ: VKTX) announced the presentation of positive final results from a proof-of-concept study of VK2809 in an ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE